Reference
Medicines and Healthcare products Regulatory Agency. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation. Drug Safety Update 13: No. 3, Oct 2019. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/840565/Oct-2019-PDF.pdf
Rights and permissions
About this article
Cite this article
Gastrointestinal CMV infection/reactivation with nivolumab. Reactions Weekly 1777, 2 (2019). https://doi.org/10.1007/s40278-019-70587-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-70587-7